<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">3y9cfQ965VL96JcQjGxhLff</article-id>
      <article-id pub-id-type="other">00007</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000300007</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600307</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Associa&#231;&#227;o entre &#225;cido &#250;rico e vari&#225;veis de risco cardiovascular em uma popula&#231;&#227;o n&#227;o hospitalar</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Barbosa</surname>
            <given-names>Monica Cristina Campos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brand&#227;o</surname>
            <given-names>Andr&#233;a Araujo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pozzan</surname>
            <given-names>Roberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magalh&#227;es</surname>
            <given-names>Maria Eliane Campos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campana</surname>
            <given-names>&#201;rika Maria Gon&#231;alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fonseca</surname>
            <given-names>Flavia Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pizzi</surname>
            <given-names>Oswaldo Luiz</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Freitas</surname>
            <given-names>Elizabete Viana de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brand&#227;o</surname>
            <given-names>Ayrton Pires</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade do Estado do Rio de Janeiro</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>3</issue>
      <fpage>212</fpage>
      <lpage>218</lpage>
      <history>
        <date date-type="rev-recd">
          <day>24</day>
          <month>06</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>09</day>
          <month>03</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>07</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A associa&#231;&#227;o entre &#225;cido &#250;rico (AU) e as vari&#225;veis de risco cardiovascular permanece controversa em estudos epidemiol&#243;gicos. OBJETIVO: Avaliar a associa&#231;&#227;o entre o AU, press&#227;o arterial (PA), &#237;ndices antropom&#233;tricos e vari&#225;veis metab&#243;licas em popula&#231;&#227;o n&#227;o hospitalar estratificada por quintis de AU. M&#201;TODOS: Em estudo observacional transversal, foram avaliados 756 indiv&#237;duos (369M), com idade de 50,3 &#177; 16,12 anos, divididos em quintis de AU. Foram obtidos PA, &#237;ndice de massa corporal (IMC), circunfer&#234;ncia abdominal (CA), AU, glicose, insulina, HOMA-IR, colesterol (CT), LDL-c, HDL-c, triglicer&#237;deos (TG), creatinina (C). Foi calculada a taxa de filtra&#231;&#227;o glomerular estimada (TFGE) e considerada hipertens&#227;o arterial (HA) quando a PA &gt; 140x90 mmHg, sobrepeso/obesidade (S/O) quando IMC &gt; 25 kg/m&#178; e s&#237;ndrome metab&#243;lica (SM) de acordo com a I Diretriz Brasileira de SM. RESULTADOS: 1) N&#227;o houve diferen&#231;a entre os grupos na distribui&#231;&#227;o por sexo e faixa et&#225;ria; 2) Os maiores quintis de AU apresentaram maiores m&#233;dias de idade (p &lt; 0,01), IMC, CA (p &lt; 0,01), PAS, PAD (p &lt; 0,001), CT, LDL-c, TG (p &lt; 0,01), C e TFGE (p &lt; 0,001) e menor m&#233;dia de HDL-c (p &lt; 0,001); 3) O grupo com maior quintil de AU mostrou maiores preval&#234;ncias de HA, S/O e SM (p &lt; 0,001); 4) Maiores percentuais dos menores quintis de insulina (p &lt; 0,02) e de HOMA-IR (p &lt; 0,01) foram encontrados nos menores quintis de AU; 5) Em an&#225;lise de regress&#227;o log&#237;stica, o AU e as vari&#225;veis que comp&#245;em a SM apresentaram-se associados &#224; ocorr&#234;ncia de SM (p &lt; 0,01). CONCLUS&#195;O: Maiores quintis de &#225;cido &#250;rico associaram-se a pior perfil de risco cardiovascular e a pior perfil de fun&#231;&#227;o renal na amostra populacional n&#227;o hospitalar estudada.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Doen&#231;as cardiovasculares</kwd>
        <kwd>&#225;cido &#250;rico</kwd>
        <kwd>hipertens&#227;o</kwd>
        <kwd>fatores de risco</kwd>
        <kwd>s&#237;ndrome metab&#243;lica</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>26</day>
        <month>01</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>Associa&#231;&#227;o entre &#225;cido &#250;rico e vari&#225;veis de risco cardiovascular em uma popula&#231;&#227;o n&#227;o hospitalar</bold>
    </p>
    <p>
      <bold>Monica Cristina Campos Barbosa; Andr&#233;a Araujo Brand&#227;o; Roberto Pozzan; Maria Eliane Campos Magalh&#227;es; &#201;rika Maria Gon&#231;alves Campana; Flavia Lopes Fonseca; Oswaldo Luiz Pizzi; Elizabete Viana de Freitas; Ayrton Pires Brand&#227;o</bold>
    </p>
    <p>Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="ntb">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A associa&#231;&#227;o entre &#225;cido &#250;rico (AU) e as vari&#225;veis de risco cardiovascular permanece controversa em estudos epidemiol&#243;gicos. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a associa&#231;&#227;o entre o AU, press&#227;o arterial (PA), &#237;ndices antropom&#233;tricos e vari&#225;veis metab&#243;licas em popula&#231;&#227;o n&#227;o hospitalar estratificada por quintis de AU. </p>
    <p><bold>M&#201;TODOS:</bold> Em estudo observacional transversal, foram avaliados 756 indiv&#237;duos (369M), com idade de 50,3 &#177; 16,12 anos, divididos em quintis de AU. Foram obtidos PA, &#237;ndice de massa corporal (IMC), circunfer&#234;ncia abdominal (CA), AU, glicose, insulina, HOMA-IR, colesterol (CT), LDL-c, HDL-c, triglicer&#237;deos (TG), creatinina (C). Foi calculada a taxa de filtra&#231;&#227;o glomerular estimada (TFGE) e considerada hipertens&#227;o arterial (HA) quando a PA <underline>&gt;</underline> 140x90 mmHg, sobrepeso/obesidade (S/O) quando IMC <underline>&gt;</underline> 25 kg/m<sup>2</sup> e s&#237;ndrome metab&#243;lica (SM) de acordo com a I Diretriz Brasileira de SM. </p>
    <p><bold>RESULTADOS:</bold> 1) N&#227;o houve diferen&#231;a entre os grupos na distribui&#231;&#227;o por sexo e faixa et&#225;ria; 2) Os maiores quintis de AU apresentaram maiores m&#233;dias de idade (p &lt; 0,01), IMC, CA (p &lt; 0,01), PAS, PAD (p &lt; 0,001), CT, LDL-c, TG (p &lt; 0,01), C e TFGE (p &lt; 0,001) e menor m&#233;dia de HDL-c (p &lt; 0,001); 3) O grupo com maior quintil de AU mostrou maiores preval&#234;ncias de HA, S/O e SM (p &lt; 0,001); 4) Maiores percentuais dos menores quintis de insulina (p &lt; 0,02) e de HOMA-IR (p &lt; 0,01) foram encontrados nos menores quintis de AU; 5) Em an&#225;lise de regress&#227;o log&#237;stica, o AU e as vari&#225;veis que comp&#245;em a SM apresentaram-se associados &#224; ocorr&#234;ncia de SM (p &lt; 0,01). </p>
    <p><bold>CONCLUS&#195;O:</bold> Maiores quintis de &#225;cido &#250;rico associaram-se a pior perfil de risco cardiovascular e a pior perfil de fun&#231;&#227;o renal na amostra populacional n&#227;o hospitalar estudada. (Arq Bras Cardiol. 2011; [online].ahead print, PP.0-0)</p>
    <p><bold>Palavras-chave:</bold> Doen&#231;as cardiovasculares/epidemiologia, &#225;cido &#250;rico, hipertens&#227;o, fatores de risco, s&#237;ndrome metab&#243;lica.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Embora os fatores de risco cl&#225;ssicos j&#225; tenham seu papel bem estabelecido no contexto das DCV, diversas condi&#231;&#245;es emergentes, denominadas marcadores de risco, ainda n&#227;o t&#234;m esta associa&#231;&#227;o definitivamente comprovada. Estudos se fazem necess&#225;rios para compreender o verdadeiro papel que desempenham nesse cen&#225;rio e se de fato poder&#227;o agregar valor na identifica&#231;&#227;o precoce de indiv&#237;duos sob risco de desenvolver DCV. Dentre estes estudos, destaca-se o do &#225;cido &#250;rico, que tem se comportado como um fator de risco cardiovascular em v&#225;rios estudos longitudinais<sup>1-5</sup>. Entretanto, a presen&#231;a de vari&#225;veis de confus&#227;o, como obesidade, consumo de &#225;lcool, idade, diabete e uso de diur&#233;ticos, dificultaram, at&#233; o presente momento, estabelecer de forma inequ&#237;voca o papel do &#225;cido &#250;rico como um fator de risco independente para eventos cardiovasculares.</p>
    <p>A associa&#231;&#227;o entre hiperuricemia e hipertens&#227;o arterial vem sendo observada h&#225; mais de um s&#233;culo<sup>1</sup>, mas permanece obscuro se a hipeuricemia tem um papel causal na hipertens&#227;o arterial ou se &#233; meramente um marcador do processo fisiopatol&#243;gico. Recentes pesquisas no campo experimental estabeleceram poss&#237;veis mecanismos pelos quais a hiperuricemia poderia causar hipertens&#227;o. Em modelos animais, o &#225;cido &#250;rico causou diminui&#231;&#227;o da &#243;xido n&#237;trico sintetase, inj&#250;ria da arter&#237;ola aferente, aumento na produ&#231;&#227;o de renina e les&#227;o tubular renal<sup>6,7</sup>. Mais ainda, em ratos, tamb&#233;m foi demonstrada estreita correla&#231;&#227;o entre hiperuricemia e s&#237;ndrome metab&#243;lica por prov&#225;vel mecanismo envolvendo a inibi&#231;&#227;o da fun&#231;&#227;o endotelial<sup>8</sup>. Sabe-se que a insulina necessita de &#243;xido n&#237;trico para estimular a capta&#231;&#227;o da glicose e a disponibilidade do &#243;xido n&#237;trico est&#225; diminu&#237;da quando ocorre hiperuricemia<sup>9</sup>.</p>
    <p>Neste contexto, a inser&#231;&#227;o do AU como vari&#225;vel para a estratifica&#231;&#227;o de risco cardiovascular pode ser interessante, por ser um exame de f&#225;cil realiza&#231;&#227;o e de baixo custo, podendo ser &#250;til na pr&#225;tica cl&#237;nica, especialmente em portadores de s&#237;ndrome metab&#243;lica e hipertens&#227;o arterial. </p>
    <p>O presente estudo tem por objetivo avaliar a associa&#231;&#227;o entre o &#225;cido &#250;rico e as vari&#225;veis de risco cardiovascular em uma popula&#231;&#227;o n&#227;o hospitalar, brasileira, com ampla varia&#231;&#227;o de idade.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Estudo transversal cuja amostra foi obtida a partir de um banco de dados de uma popula&#231;&#227;o n&#227;o hospitalar do setor de hipertens&#227;o arterial do Hospital Universit&#225;rio Pedro Ernesto da Universidade do Estado do Rio de Janeiro (UERJ). A amostra foi originada de pacientes submetidos a exames admissionais, pr&#233;-operat&#243;rios de cirurgias n&#227;o card&#237;acas e avalia&#231;&#227;o cl&#237;nica para atividade f&#237;sica regular. Foram considerados eleg&#237;veis para inclus&#227;o nesse estudo, indiv&#237;duos de ambos os sexos com mais de 20 anos, que tivessem em seus registros dados demogr&#225;ficos, de hist&#243;ria cl&#237;nica e de exame f&#237;sico, al&#233;m de avalia&#231;&#227;o laboratorial com dosagem de &#225;cido &#250;rico, glicemia, l&#237;pides s&#233;ricos e creatinina. </p>
    <p>A amostra foi constitu&#237;da por 756 indiv&#237;duos com mais de 20 anos (m&#233;dia de 50,3 anos), sendo 369 do sexo masculino (48,8%). Os pacientes foram distribu&#237;dos por estratos de 20 anos.</p>
    <p>Em todos, foram colhidos dados demogr&#225;ficos e realizada uma avalia&#231;&#227;o cl&#237;nica para coleta de hist&#243;ria m&#233;dica e realiza&#231;&#227;o de exame f&#237;sico constando de aferi&#231;&#227;o de press&#227;o arterial, peso e altura para c&#225;lculo do IMC, medida da circunfer&#234;ncia abdominal. Ainda foi colhida amostra sangu&#237;nea, em jejum de 12 horas, para determina&#231;&#227;o dos seguintes exames laboratoriais: glicose, insulina, HOMA IR<sup>10</sup>, &#225;cido &#250;rico, creatinina. Foi tamb&#233;m calculada a taxa de filtra&#231;&#227;o glomerular, estimada pela f&#243;rmula de Cockroft-Gault (140-idade x peso/ creatinina x72 para os homens, e, para as mulheres, multiplicado pelo fator de corre&#231;&#227;o de 0,85), colesterol total, HDL-c, triglicer&#237;deos e o LDL-c, atrav&#233;s da f&#243;rmula de Friedwald.</p>
    <p>A dosagem de insulina e o c&#225;lculo do HOMA-IR foram realizados em 498 pacientes, nos quais a dosagem de insulina foi realizada e o HOMA-IR foi calculado de acordo com a f&#243;rmula: insulina de jejum x glicose plasm&#225;tica de jejum/ 405. O diagn&#243;stico de S&#237;ndrome Metab&#243;lica foi considerado segundo os crit&#233;rios da I Diretriz de S&#237;ndrome Metab&#243;lica<sup>11</sup>. O diagn&#243;stico de hipertens&#227;o arterial foi considerado conforme a V Diretriz Brasileira de Hipertens&#227;o Arterial<sup>12</sup>.</p>
    <p>A amostra foi estratificada por quintis de &#225;cido &#250;rico segundo o sexo, tendo sido constitu&#237;dos 5 grupos de G1 a G5, em ordem crescente dos quintis de &#225;cido &#250;rico. Para o sexo masculino (M), os valores correspondentes aos quintis de &#225;cido &#250;rico foram <underline>&lt;</underline> 4, 5, &gt; 4,5 e <underline>&lt;</underline> 5, 2, &gt; 5,2 e <underline>&lt;</underline> 5, 9, &gt; 5,9 e <underline>&lt;</underline> 6, 5, e &gt; 6,5 mg/dl. Para o sexo feminino (F), os valores encontrados foram <underline>&lt;</underline> 3, 26, &gt; 3,26 e <underline>&lt;</underline> 3, 9, &gt; 3,9 e <underline>&lt;</underline> 4,5 e &gt; 4,5 e <underline>&lt;</underline> 5,24 e &gt; 5,24 mg/dl, respectivamente para o primeiro, segundo, terceiro, quarto e quinto quintis de &#225;cido &#250;rico. </p>
    <p>Os dados foram analisados atrav&#233;s do programa estat&#237;stico "<italic>SPSS for Windows</italic>", vers&#227;o 8.0.0, <italic>Copyright SPSS Inc</italic>. 1989 - 1997.</p>
    <p>Foram utilizados os seguintes m&#233;todos estat&#237;sticos, considerando-se 0,05 ou 5,0% (p = 0,05) o n&#237;vel de rejei&#231;&#227;o da hip&#243;tese de nulidade: </p>
    <disp-quote>
      <p>&#149;<italic> An&#225;lise de vari&#226;ncia (F) - </italic>utilizada para a compara&#231;&#227;o das m&#233;dias das vari&#225;veis que apresentam distribui&#231;&#227;o normal e que tenham homogeneidade de vari&#226;ncias pelo teste de Bartley.</p>
      <p>&#149; <italic> Teste de Tukey - </italic>usado como complementa&#231;&#227;o da an&#225;lise de Vari&#226;ncia, para a compara&#231;&#227;o das m&#233;dias das vari&#225;veis 2 a 2.</p>
      <p>&#149;<italic> Teste do qui-quadrado (</italic>c<italic><sup>2</sup>) - </italic>utilizado para a compara&#231;&#227;o das distribui&#231;&#245;es de frequ&#234;ncia das vari&#225;veis categ&#243;ricas de amostras independentes. </p>
      <p>&#149;<italic> Teste de Correla&#231;&#227;o de Pearson - </italic>empregado para analisar a correla&#231;&#227;o entre vari&#225;veis cont&#237;nuas. </p>
    </disp-quote>
    <p>Este estudo foi aprovado pelo Comit&#234; de &#201;tica do Hospital Universit&#225;rio Pedro Ernesto, sob n&#250;mero 2322-CEP/HUPE, em 10 de dezembro de 2008.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>A distribui&#231;&#227;o dos indiv&#237;duos foi uniforme por g&#234;nero e por faixas et&#225;rias analisadas (<xref ref-type="table" rid="aop00211tab01m">Tabela 1</xref>).</p>
    <p content-type="asset">
      <table-wrap id="aop00211tab01m">
        <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gt01.jpg"/></table-wrap>
    </p>
    <p>As m&#233;dias de PAS, PAD, colesterol total, triglicer&#237;deos e de creatinina aumentaram significativamente quanto maiores foram os quintis de &#225;cido &#250;rico (<xref ref-type="table" rid="aop00211tab02m">Tabela 2</xref>). Para o HDL-c e para a taxa de filtra&#231;&#227;o glomerular estimada ocorreu o contr&#225;rio: as maiores m&#233;dias destas vari&#225;veis estavam presentes nos menores quintis de &#225;cido &#250;rico (<xref ref-type="table" rid="aop00211tab02m">Tabela 2</xref>). </p>
    <p content-type="asset">
      <table-wrap id="aop00211tab02m">
        <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gt02.jpg"/></table-wrap>
    </p>
    <p>Na amostra total, foi encontrada uma preval&#234;ncia de 48,3% de hipertens&#227;o arterial, 33,6% de s&#237;ndrome metab&#243;lica, 62,4% de sobrepeso e obesidade, 55,9% de hipercolesterolemia, 14,9% de glicemia de jejum alterada, 4,1% de diabete, 24,9% de hipertrigliceridemia e 33,9% de HDL baixo (<xref ref-type="table" rid="aop00211tab03m">Tabela 3</xref>).</p>
    <p content-type="asset">
      <table-wrap id="aop00211tab03m">
        <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gt03.jpg"/></table-wrap>
    </p>
    <p>As preval&#234;ncias de hipertens&#227;o arterial, sobrepeso/obesidade (<xref ref-type="table" rid="aop00211tab03m">Tabela 3</xref>) e s&#237;ndrome metab&#243;lica (<xref ref-type="fig" rid="aop00211fig01m">Figura 1</xref>) foram significativamente maiores nos maiores quintis de &#225;cido &#250;rico (p &lt; 0,0001).</p>
    <p content-type="asset">
      <fig id="aop00211fig01m">
        <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gf01.jpg"/></fig>
    </p>
    <p>Em rela&#231;&#227;o &#224; insulina e ao HOMA-IR, houve maior predom&#237;nio dos maiores quintis de insulina e HOMA-IR nos quintis superiores de &#225;cido &#250;rico com c<sup>2</sup> = 35,761 e p = 0,003 para HOMA-IR e c<sup>2</sup> = 31,393 e p = 0,012 para insulina (<xref ref-type="fig" rid="aop00211fig02m">Figuras 2</xref> e <xref ref-type="fig" rid="aop00211fig03m">3</xref>). </p>
    <p content-type="asset">
      <fig id="aop00211fig02m">
        <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gf02.jpg"/></fig>
    </p>
    <p content-type="asset">
      <fig id="aop00211fig03m">
        <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gf03.jpg"/></fig>
    </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Este estudo trouxe contribui&#231;&#245;es para o melhor entendimento do comportamento do &#225;cido &#250;rico em rela&#231;&#227;o &#224;s vari&#225;veis cl&#237;nicas, metab&#243;licas e de fun&#231;&#227;o renal associadas a maior risco cardiovascular, mormente por se tratar de um trabalho com um n&#250;mero significativo de indiv&#237;duos de origem n&#227;o hospitalar, em uma popula&#231;&#227;o brasileira, cujos dados s&#227;o pouco dispon&#237;veis at&#233; o presente momento. V&#225;rios estudos populacionais demonstraram ser o &#225;cido &#250;rico vari&#225;vel independente de risco para fatores de risco cardiovasculares<sup>2-5,13-25</sup>.</p>
    <p>A popula&#231;&#227;o estudada no presente estudo &#233; uma amostra de conveni&#234;ncia, sem c&#225;lculo de tamanho amostral, e, como tal, pode n&#227;o refletir as caracter&#237;sticas da popula&#231;&#227;o em geral. Por outro lado, o fato de ter tamanho representativo e ser de origem n&#227;o hospitalar pode ter atenuado o poss&#237;vel vi&#233;s de sele&#231;&#227;o.</p>
    <p>Em rela&#231;&#227;o &#224; m&#233;dia de idade dos indiv&#237;duos dessa s&#233;rie (50,3 anos), n&#227;o h&#225; diferen&#231;as significativas em rela&#231;&#227;o a maior parte dos estudos sobre o tema<sup>3,18</sup>, excetuando-se os trabalhos realizados em crian&#231;as e adolescentes, como no estudo de Bogalusa<sup>14</sup> ou no ensaio conduzido por Forman e cols.<sup>26</sup>, cuja m&#233;dia de idade foi de 61 anos.</p>
    <p>Com rela&#231;&#227;o &#224; presen&#231;a de fatores de risco, foi observada uma preval&#234;ncia aumentada de HAS no presente estudo (48,3%), em contraste com a taxa esperada de 31,0% para a regi&#227;o sudeste brasileira. Uma poss&#237;vel explica&#231;&#227;o para esse fato pode ser a faixa et&#225;ria desses indiv&#237;duos, uma vez que foram inclu&#237;dos pacientes idosos (acima de 80 anos) e ainda que 30,0% da popula&#231;&#227;o do estudo tinham mais de 60 anos de idade, faixa et&#225;ria na qual a preval&#234;ncia de hipertens&#227;o arterial &#233; reconhecidamente maior.</p>
    <p>A SM foi encontrada em 34,5% desses indiv&#237;duos, ultrapassando as preval&#234;ncias descritas em diversas s&#233;ries<sup>24,27</sup>. Cabe lembrar a aus&#234;ncia de dados nacionais a tal respeito para efeito de compara&#231;&#227;o<sup>28</sup>. Entretanto, diversos estudos t&#234;m apontado preval&#234;ncias de SM que variaram de 8,0% a 70,7%, dependendo da faixa et&#225;ria. &#201; poss&#237;vel que as taxas observadas no presente estudo devam-se n&#227;o s&#243; a faixa et&#225;ria mais elevada desses indiv&#237;duos, como tamb&#233;m por ser esta uma popula&#231;&#227;o com mais de 60,0% de preval&#234;ncia de obesidade.</p>
    <p>Para o diabete, foi encontrada uma preval&#234;ncia semelhante &#224;quela observada em nosso pa&#237;s, que &#233; de 4,0%<sup>2</sup> em grandes s&#233;ries, como o estudo de Framigham<sup>2</sup>, onde constatou-se 2,7% de diabete na popula&#231;&#227;o estudada.</p>
    <p>Do ponto de vista hemodin&#226;mico, nota-se que houve maiores m&#233;dias de press&#227;o arterial nos maiores quintis de &#225;cido &#250;rico, correspondendo aos resultados tamb&#233;m encontrados por Conen e cols.<sup>29</sup>. </p>
    <p>Quanto &#224; preval&#234;ncia de hipertens&#227;o arterial pelos quintis de &#225;cido &#250;rico, foi demonstrado claramente haver uma associa&#231;&#227;o significativa entre tais vari&#225;veis. Esse tem sido o resultado encontrado em diversas publica&#231;&#245;es, conforme podemos verificar desde 1994 com o <italic>The Olivetti Heart Study</italic><sup>23</sup>, onde o &#225;cido &#250;rico esteve associado a fatores de risco cardiovasculares, como a hipertens&#227;o arterial, ou, como no estudo conduzido por Perlstein e cols.<sup>4</sup>, durante 21 anos, em 2.062 indiv&#237;duos, onde a hipertens&#227;o arterial tamb&#233;m se associou a maiores quintis de &#225;cido &#250;rico. De forma semelhante, a s&#233;rie de Mellen e cols.<sup>3</sup>, em seguimento de 9 anos, com 9.104 indiv&#237;duos bi-&#233;tnicos e de ambos os sexos, revelou que a hipertens&#227;o arterial foi mais prevalente nos pacientes com maiores n&#237;veis de &#225;cido &#250;rico. </p>
    <p>A explica&#231;&#227;o biol&#243;gica para tal fato tem como ponto de apoio as pesquisas realizadas em modelo animal com ratos, onde, ap&#243;s a indu&#231;&#227;o de hiperuricemia, houve desenvolvimento de hipertens&#227;o arterial por prov&#225;vel redu&#231;&#227;o do &#243;xido n&#237;trico na m&#225;cula densa renal e por est&#237;mulo direto do sistema renina-angiotensina, sendo ambos os mecanismos causadores de vasoconstri&#231;&#227;o e, portanto, de eleva&#231;&#227;o da press&#227;o arterial<sup>6,7</sup>.</p>
    <p>No entanto, na outra ponta dessa argumenta&#231;&#227;o, encontra-se a possibilidade de que o aumento do &#225;cido &#250;rico possa estar presente em condi&#231;&#245;es cl&#237;nicas sabidamente pr&#243;-inflamat&#243;rias, como a HAS e a SM, por sua a&#231;&#227;o antioxidante e, portanto, representar apenas um mecanismo bioqu&#237;mico de defesa<sup>30-32</sup> contra a progress&#227;o da aterosclerose. Assim, n&#227;o seria um fator independente de risco para essas s&#237;ndromes, mas, antes, apenas parte do cortejo cl&#237;nico.</p>
    <p>Em rela&#231;&#227;o &#224;s vari&#225;veis metab&#243;licas, as preval&#234;ncias de colesterol, triglicer&#237;deos e de intoler&#226;ncia &#224; glicose foram significativamente maiores nos maiores quintis de AU. A associa&#231;&#227;o com colesterol e triglicer&#237;deos tamb&#233;m foi encontrada na popula&#231;&#227;o estudada no <italic>Normative Aging Study.</italic> Quanto ao HDL-c, este estudo demonstrou associa&#231;&#227;o inversa com os quintis de &#225;cido &#250;rico e o mesmo foi verificado nos 425 pacientes estudados por Zocalli e cols.<sup>27</sup>. </p>
    <p>Na an&#225;lise da distribui&#231;&#227;o dos quintis de insulina e HOMA-IR, em rela&#231;&#227;o aos quintis de &#225;cido &#250;rico, este trabalho mostrou de forma significativa uma associa&#231;&#227;o entre maiores quintis de &#225;cido &#250;rico e maiores quintis tanto de insulina como de HOMA-IR, achado consistente com a s&#233;rie conduzida por Forman e cols.<sup>26</sup>. Para o HOMA-IR, Ishizaka e cols.<sup>24</sup> demonstraram maiores preval&#234;ncias desta vari&#225;vel por quintis de &#225;cido &#250;rico. Quanto &#224; presen&#231;a de diabete, o presente estudo mostrou que a preval&#234;ncia desta patologia foi significativamente maior nos grupos com maiores n&#237;veis de &#225;cido &#250;rico, resultado consistente com grandes estudos longitudinais, como o estudo de Framingham<sup>2</sup> ou a coorte de 9.104 indiv&#237;duos do estudo ARIC<sup>3</sup>. Esses achados sugerem que a hiperuricemia esteja associada &#224; resist&#234;ncia insul&#237;nica, condi&#231;&#227;o subjacente &#224; s&#237;ndrome metab&#243;lica.</p>
    <p>Em rela&#231;&#227;o &#224; s&#237;ndrome metab&#243;lica, encontrou-se, tamb&#233;m, maior preval&#234;ncia nos grupos com maiores n&#237;veis de &#225;cido &#250;rico e, do mesmo modo, a literatura aponta esta associa&#231;&#227;o, como podemos observar no estudo conduzido por Kawadae cols.<sup>25</sup>, onde 981 trabalhadores japoneses foram avaliados e verificou-se a associa&#231;&#227;o entre s&#237;ndrome metab&#243;lica e hiperuricemia. </p>
    <p>O grupo de Ishizaka<sup>24 </sup>tamb&#233;m demonstrou de maneira significativa a associa&#231;&#227;o entre s&#237;ndrome metab&#243;lica e AU, ao estudar, de forma transversal, 8.144 indiv&#237;duos de ambos os sexos, estratificados por quartis de &#225;cido &#250;rico. A maior preval&#234;ncia de s&#237;ndrome metab&#243;lica por n&#237;veis crescentes de &#225;cido &#250;rico tamb&#233;m foi demonstrada no estudo realizado por Choi e Ford<sup>16,17</sup> utilizando dados do NHANES. Em alguns outros trabalhos, como o de Coutinho e cols.<sup>33</sup> e Desai e cols.<sup>15</sup>, nota-se que o &#225;cido &#250;rico esteve associado a componentes que constituem a s&#237;ndrome metab&#243;lica, sendo esta associa&#231;&#227;o tanto maior quanto maior o n&#250;mero de componentes presentes desta s&#237;ndrome.</p>
    <p>Recentemente, em estudo realizado no Brasil por Franco e cols.<sup>34</sup>, em pacientes hipertensos de Cuiab&#225;, observou-se maior preval&#234;ncia de SM em pacientes portadores de hiperuricemia<sup>34</sup>.</p>
    <p>Como limita&#231;&#227;o do presente estudo, destaca-se que esta n&#227;o &#233; uma amostra de base populacional. Entretanto, o n&#250;mero de indiv&#237;duos estudados &#233; bastante expressivo e corresponde a um cen&#225;rio real de avalia&#231;&#227;o de fatores de risco cardiovascular em uma popula&#231;&#227;o n&#227;o hospitalar. Dados como o uso de medicamentos, etilismo e presen&#231;a de menopausa n&#227;o estavam dispon&#237;veis e s&#227;o fatores que podem interferir, ao menos parcialmente, nos resultados encontrados. Al&#233;m disso, trata-se de estudo transversal, permitindo t&#227;o somente a an&#225;lise de associa&#231;&#227;o de vari&#225;veis, sem infer&#234;ncias temporais.</p>
    <p>
      <bold>Conclus&#245;es e Perspectivas</bold>
    </p>
    <p>O presente estudo indica a possibilidade de que o &#225;cido &#250;rico esteja associado &#224;s vari&#225;veis de risco cardiovascular e &#224; s&#237;ndrome metab&#243;lica, podendo ser &#250;til na avalia&#231;&#227;o do risco cardiovascular individual.</p>
    <p>A exist&#234;ncia de uma base racional fisiopatol&#243;gica para explicar a rela&#231;&#227;o do &#225;cido &#250;rico com os fatores de risco cardiovascular, aliada &#224; facilidade de mensura&#231;&#227;o do &#225;cido &#250;rico e da exist&#234;ncia de terapia apropriada para trat&#225;-lo, refor&#231;am a necessidade de novas pesquisas para compreender melhor a sua participa&#231;&#227;o no cen&#225;rio das doen&#231;as cardiovasculares.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de disserta&#231;&#227;o de Mestrado de Monica Cristina Campos Barbosa pela Universidade do Estado do Rio de Janeiro.</p>
    <p>
      <fn id="ntb" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Andr&#233;a Araujo Brand&#227;o </p>
        <p> Rua General Tasso Fragoso, 24/503 - Lagoa </p>
        <p> 22470-170 - Rio de Janeiro, RJ - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="aabrandao@cardiol.br">aabrandao@cardiol.br</email>, </p>
        <p>
          <email xlink:href="andreaabrandao@terra.com.br">andreaabrandao@terra.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 09/03/10; revisado recebido em 24/06/10; aceito em 16/07/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Mohamed F. On chronic Bright's disease, and its essential symptoms. Lancet. 1879; 1: 399-401. apud: Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease and metabolic syndrome. Cleve Clin J Med. 2006; 73 (12): 1059-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of uric acid in hypertension, renal disease and metabolic syndrome</article-title>
          <source>Cleve Clin J Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1059</fpage>
          <lpage>63</lpage>
          <issue>12</issue>
          <volume>73</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Heinig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RJ.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Sunstrom J, Sullivan L, D'agostinho R, Levy D, Kannnel W, Vasan R. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005; 45 (1): 28-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence</article-title>
          <source>Hypertension</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>28</fpage>
          <lpage>33</lpage>
          <issue>1</issue>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sunstrom</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>D'agostinho</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kannnel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Vasan</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Mellen PB, Bleyer AJ, Erlinger TP, Evans G, Nieto FJ, Wagenknecht L, et al. Serum acid uric predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006; 48 (6):1037-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum acid uric predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study</article-title>
          <source>Hypertension</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1037</fpage>
          <lpage>42</lpage>
          <issue>6</issue>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mellen</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Bleyer</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Erlinger</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nieto</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Wagenknecht</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Litonjua AA, Vokonas P, et al. Uric acid and the development of hypertension: the Normative Aging Study. Hypertension. 2006; 48 (6): 1031-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Uric acid and the development of hypertension: the Normative Aging Study</article-title>
          <source>Hypertension</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1031</fpage>
          <lpage>6</lpage>
          <issue>6</issue>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Perlstein</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Gumieniak</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Sparrow</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Litonjua</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Vokonas</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007; 49 (2): 298-303.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hyperuricemia and incidence of hypertension among men without metabolic syndrome</article-title>
          <source>Hypertension</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>298</fpage>
          <lpage>303</lpage>
          <issue>2</issue>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Krishnan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kwoh</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Schumacher</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Kuller</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Mazzali M, Hughes J, Kim Y, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001; 38 (5): 1101-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism</article-title>
          <source>Hypertension</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1101</fpage>
          <lpage>6</lpage>
          <issue>5</issue>
          <volume>38</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mazzali</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jefferson</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal. 2002; 282 (6): F991- F7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism</article-title>
          <source>Am J Physiol Renal</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>F991</fpage>
          <lpage> F7</lpage>
          <issue>6</issue>
          <volume>282</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mazzali</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kanellis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Nakagawa T, Hu H, Zhariov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose e-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006; 290 (3): F625-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A causal role for uric acid in fructose e-induced metabolic syndrome</article-title>
          <source>Am J Physiol Renal Physiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>625</fpage>
          <lpage>31</lpage>
          <issue>3</issue>
          <volume>290</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nakagawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhariov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tuttle</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Short</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Glushakova</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease and metabolic syndrome. Cleve Clin J Med. 2006; 73 (12): 1059-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of uric acid in hypertension, renal disease and metabolic syndrome</article-title>
          <source>Cleve Clin J Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1059</fpage>
          <lpage>63</lpage>
          <issue>12</issue>
          <volume>73</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Heinig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RJ.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Matthews DR, Hosker JP, Rudenki AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28 (7): 412-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Homeostasis model assessment Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title>
          <source>Diabetologia</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>412</fpage>
          <lpage>9</lpage>
          <issue>7</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Matthews</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Hosker</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Rudenki</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Naylor</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Treacher</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>RC.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Brand&#227;o AP, Nogueira AR, Oliveira JE, Guimar&#227;es JI, Suplicy H, Brand&#227;o AA. (orgs.). / Sociedade Brasileira de Cardiologia. I Diretriz brasileira de diagn&#243;stico e tratamento da s&#237;ndrome metab&#243;lica. Arq Bras Cardiol. 2005; 84 (supl 1): 3-28.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>I Diretriz brasileira de diagn&#243;stico e tratamento da s&#237;ndrome metab&#243;lica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>3</fpage>
          <lpage>28</lpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brand&#227;o</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Nogueira</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Suplicy</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brand&#227;o</surname>
              <given-names>AA.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Mion Jr D, Kohlmann Jr O, Machado CA, Amodeo C, Gomes MAM, Praxedes JN, et al. / Sociedade Brasileira de Cardiologia. V Diretrizes brasileiras de hipertens&#227;o arterial. Arq Bras Cardiol. 2007; 89 (3): e24-e79.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>V Diretrizes brasileiras de hipertens&#227;o arterial</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>e24</fpage>
          <lpage>e79</lpage>
          <issue>3</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mion Jr</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kohlmann Jr</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Machado</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Amodeo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>MAM</given-names>
            </name>
            <name>
              <surname>Praxedes</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005; 45 (5): 991-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum uric acid and target organ damage in primary hypertension</article-title>
          <source>Hypertension</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>991</fpage>
          <lpage>6</lpage>
          <issue>5</issue>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Viazzi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Parodi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Leoncini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Parodi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Falqui</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ratto</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Alper AB, Chen W, Yau L, Srinivans SR, Berenson G, Hamm LL. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension. 2005; 45 (1): 34-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study</article-title>
          <source>Hypertension</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>34</fpage>
          <lpage>8</lpage>
          <issue>1</issue>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Alper</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Yau</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Srinivans</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Berenson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hamm</surname>
              <given-names>LL.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Desai M, Santos R, Dalal D, Carvalho JA, Marten DR, Flynn JA, et al. Relation of serum uric acid with metabolic risk factors in asymptomatic middle-aged Brazilian men. J Am Coll Cardiol. 2005; 95 (7): 865-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation of serum uric acid with metabolic risk factors in asymptomatic middle-aged Brazilian men</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>865</fpage>
          <lpage>8</lpage>
          <issue>7</issue>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Desai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dalal</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Marten</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Flynn</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Choi HK, Ford ES. Prevalence of metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007; 120 (5): 442-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of metabolic syndrome in individuals with hyperuricemia</article-title>
          <source>Am J Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>442</fpage>
          <lpage>7</lpage>
          <issue>5</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>ES.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007; 115 (19): 2526-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2526</fpage>
          <lpage>32</lpage>
          <issue>19</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ford</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>HK.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid as a risk factor for cardiovascular and all cause mortality in middle-ages men. Arch Intern Med. 2004; 164 (14): 1546-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Uric acid as a risk factor for cardiovascular and all cause mortality in middle-ages men</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1546</fpage>
          <lpage>51</lpage>
          <issue>14</issue>
          <volume>164</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Niskanen</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Laaksonen</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Nyyssonen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Alfthan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lakka</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Lakka</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Epidemiology. 1999; 10 (4): 391-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort: World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease</article-title>
          <source>Epidemiology</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>391</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Liese</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Hense</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Lowel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Doring</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tietze</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Keil</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999; 131 (1): 7-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>7</fpage>
          <lpage>13</lpage>
          <issue>1</issue>
          <volume>131</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Culleton</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Bengtsson C, Lapidus L, Stendhal C, Waldestrom J. Hyperuricemia and risk of cardiovascular disease and overall death: a 12-year follow-up of participants in the population study of women in Gothemburg, Sweden. Acta Med Scand. 1988; 224 (6): 549-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hyperuricemia and risk of cardiovascular disease and overall death: a 12-year follow-up of participants in the population study of women in Gothemburg, Sweden</article-title>
          <source>Acta Med Scand</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>549</fpage>
          <lpage>55</lpage>
          <issue>6</issue>
          <volume>224</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bengtsson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lapidus</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Stendhal</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Waldestrom</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Taniguchi Y, Hayashi T, Tsumara K, Endo G, FujiiS, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka Health Survey. Hypertension. 2001; 19 (7): 1209-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka Health Survey</article-title>
          <source>Hypertension</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1209</fpage>
          <lpage>15</lpage>
          <issue>7</issue>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Taniguchi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsumara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Endo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, et al. Serum acid uric and hypertension: the Olivetti Heart Study. J Hum Hypertens. 1994; 8 (9): 677-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum acid uric and hypertension: the Olivetti Heart Study</article-title>
          <source>J Hum Hypertens</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>677</fpage>
          <lpage>81</lpage>
          <issue>9</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jossa</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Farinaro</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Panico</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Krogh</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Celentano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Galasso</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Ishizaka N, Ishizaka I, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005; 25 (5): 1038-44.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1038</fpage>
          <lpage>44</lpage>
          <issue>5</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ishizaka</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ishizaka</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Toda</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Yamakado</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Kawada T, Otsuka T, Katsumata M, Suzuki H. Serum uric acid is significantly related to the components of the metabolic syndrome in Japanese working men. J Cardiometab Syndr. 2007; 2 (3): 158-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum uric acid is significantly related to the components of the metabolic syndrome in Japanese working men</article-title>
          <source>J Cardiometab Syndr</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>158</fpage>
          <lpage>62</lpage>
          <issue>3</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kawada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Otsuka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Katsumata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18 (1): 287-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma uric acid level and risk for incident hypertension among men</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>287</fpage>
          <lpage>92</lpage>
          <issue>1</issue>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Forman</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Curhan</surname>
              <given-names>GC.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006; 17 (5): 1466-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Uric acid and endothelial dysfunction in essential hypertension</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1466</fpage>
          <lpage>71</lpage>
          <issue>5</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zoccali</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Maio</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mallamaci</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sesti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Perticone</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Minist&#233;rio da Sa&#250;de. Secretaria Executiva. DATASUS. Indicadores e dados b&#225;sicos do Brasil. Bras&#237;lia; 2007. [Acesso em 2009 nov 9]. Dispon&#237;vel em <ext-link ext-link-type="uri" xlink:href="http://www.datasus.gov.br">http://www.datasus.gov.br</ext-link></mixed-citation>
        <element-citation publication-type="book">
          <source>Indicadores e dados b&#225;sicos do Brasil</source>
          <date>
            <year>2007</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Conen D, Wietlisbach V, Bovet P, Shamaye C, Riesen W, Paccand F, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in developing country. BMC Public Health. 2004 Mar 25; 4-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in developing country</article-title>
          <source>BMC Public Health</source>
          <date>
            <day>25</day>
            <year>2004</year>
            <month>03</month>
          </date>
          <fpage>4</fpage>
          <lpage>9</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Conen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wietlisbach</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bovet</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Shamaye</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Riesen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Paccand</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000; 148 (1): 131-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?</article-title>
          <source>Atherosclerosis</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>131</fpage>
          <lpage>9</lpage>
          <issue>1</issue>
          <volume>148</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nieto</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Iribarren</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Comstock</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Cutler</surname>
              <given-names>RG.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron complexes: a new aspect of the antioxidant functions of uric acid. Biochemist J. 1986; 235 (3): 747-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Uric acid-iron complexes: a new aspect of the antioxidant functions of uric acid</article-title>
          <source>Biochemist J</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>747</fpage>
          <lpage>54</lpage>
          <issue>3</issue>
          <volume>235</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Sevanian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Muakkassah-Kelly</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Hochstein</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical- caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981; 78 (11): 6858-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Uric acid provides an antioxidant defense in humans against oxidant- and radical- caused aging and cancer: a hypothesis</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <date>
            <year>1981</year>
          </date>
          <fpage>6858</fpage>
          <lpage>62</lpage>
          <issue>11</issue>
          <volume>78</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ames</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Cathcart</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schwiers</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hochstein</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Coutinho TA, Turner ST, Peyser PA, Bielak LF, Sheedy PF, Kullo IJ. Association of serum uric acid with markers of inflammation, metabolic syndrome and subclinical coronary atherosclerosis. Am J Hypertens. 2007; 20 (1): 83-9.</mixed-citation>
        <element-citation publication-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Coutinho</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Peyser</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Bielak</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Sheedy</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Kullo</surname>
              <given-names>IJ.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>33. Franco GPP, Scala LCN, Alves CJ, Fran&#231;a VA, Casarell T, Jardim PC. S&#237;ndrome metab&#243;lica em hipertensos de Cuiab&#225;-MT: preval&#234;ncia e fatores de risco. Arq Bras Cardiol. 2009; 92 (6): 437-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>S&#237;ndrome metab&#243;lica em hipertensos de Cuiab&#225;-MT: preval&#234;ncia e fatores de risco</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>437</fpage>
          <lpage>42</lpage>
          <issue>6</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Franco</surname>
              <given-names>GPP</given-names>
            </name>
            <name>
              <surname>Scala</surname>
              <given-names>LCN</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Fran&#231;a</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Casarell</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jardim</surname>
              <given-names>PC.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Association between uric acid and cardiovascular risk variables in a non-hospitalized population</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: The association between uric acid (UA) and cardiovascular risk variables remains a controversial issue in epidemiological studies. OBJECTIVE: To evaluate the association between UA, blood pressure (BP), anthropometric indices and metabolic variables in a non-hospitalized population stratified by UA quintiles. METHODS: A cross-sectional observational study evaluated 756 individuals (369 males), aged 50.3 &#177; 16.12 years, divided in UA quintiles. BP, body mass index (BMI), abdominal circumference (AC), UA, glucose, insulin, HOMA-IR, total cholesterol (TC), LDL-c, HDL-c, triglycerides (TG) and creatinine (C) levels were obtained. The estimated glomerular filtration rate (eGFR) was calculated and arterial hypertension (AH) was considered when BP &gt; 140x90 mmHg, overweight/obesity (OW/O) was considered when BMI &gt; 25 kg/m&#178; and metabolic syndrome (MS) was established according to the I Brazilian Guideline of MS. RESULTS: 1) There was no difference between the groups regarding the distribution by sex and age range; 2) The highest UA quintiles presented higher mean age (p &lt; 0.01), BMI, AC (p &lt; 0.01), SBP, DBP (p &lt; 0.001), TC, LDL-c, TG (p &lt; 0.01), C and eGFR (p &lt; 0.001) and lower mean HDL-c (p &lt; 0.001); 3) The group with the highest UA quintile showed higher prevalence of AH, OW/O and MS (p &lt; 0.001); 4) Higher percentages of the lowest quintiles of insulin (p &lt; 0.02) and HOMA-IR (p &lt; 0.01) were observed with the lowest quintiles of UA; 5) A logistic regression analysis showed that UA and the variables that compose MS were associated with the occurrence of MS (p &lt; 0.01). CONCLUSION: Higher quintiles of uric acid were associated with a worse cardiovascular risk profile and a worse kidney function profile in the non-hospitalized population sample studied.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Cardiovascular diseases</kwd>
        <kwd>uric acid</kwd>
        <kwd>hypertension</kwd>
        <kwd>risk factors</kwd>
        <kwd>metabolic syndrome</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <fn id="nta-body2">
          <label>
            <bold>Association between uric acid and cardiovascular risk variables in a non-hospitalized population</bold>
          </label>
          <p>
            <bold>Monica Cristina Campos Barbosa; Andr&#233;a Araujo Brand&#227;o; Roberto Pozzan; Maria Eliane Campos Magalh&#227;es; &#201;rika Maria Gon&#231;alves Campana; Flavia Lopes Fonseca; Oswaldo Luiz Pizzi; Elizabete Viana de Freitas; Ayrton Pires Brand&#227;o</bold>
          </p>
        </fn>
      </p>
      <p>Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ - Brasil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> The association between uric acid (UA) and cardiovascular risk variables remains a controversial issue in epidemiological studies.</p>
      <p><bold>OBJECTIVE: </bold>To evaluate the association between UA, blood pressure (BP), anthropometric indices and metabolic variables in a non-hospitalized population stratified by UA quintiles.</p>
      <p><bold>METHODS: </bold>A cross-sectional observational study evaluated 756 individuals (369 males), aged 50.3 &#177; 16.12 years, divided in UA quintiles. BP, body mass index (BMI), abdominal circumference (AC), UA, glucose, insulin, HOMA-IR, total cholesterol (TC), LDL-c, HDL-c, triglycerides (TG) and creatinine (C) levels were obtained. The estimated glomerular filtration rate (eGFR) was calculated and arterial hypertension (AH) was considered when BP <underline>&gt;</underline> 140x90 mmHg, overweight/obesity (OW/O) was considered when BMI <underline>&gt;</underline> 25 kg/m<sup>2</sup> and metabolic syndrome (MS) was established according to the I Brazilian Guideline of MS.</p>
      <p><bold>RESULTS: </bold>1) There was no difference between the groups regarding the distribution by sex and age range; 2) The highest UA quintiles presented higher mean age (p &lt; 0.01), BMI, AC (p &lt; 0.01), SBP, DBP (p &lt; 0.001), TC, LDL-c, TG (p &lt; 0.01), C and eGFR (p &lt; 0.001) and lower mean HDL-c (p &lt; 0.001); 3) The group with the highest UA quintile showed higher prevalence of AH, OW/O and MS (p &lt; 0.001); 4) Higher percentages of the lowest quintiles of insulin (p &lt; 0.02) and HOMA-IR (p &lt; 0.01) were observed with the lowest quintiles of UA; 5) A logistic regression analysis showed that UA and the variables that compose MS were associated with the occurrence of MS (p &lt; 0.01).</p>
      <p><bold>CONCLUSION: </bold>Higher quintiles of uric acid were associated with a worse cardiovascular risk profile and a worse kidney function profile in the non-hospitalized population sample studied. </p>
      <p><bold>Keywords:</bold> Cardiovascular diseases/epidemiology; uric acid; hypertension; risk factors; metabolic syndrome.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Although the role of classic risk factors have been well-established in the context of cardiovascular disease (CVD), several emergent conditions, called risk marker, have not had their association definitely demonstrated. Studies are necessary to understand the actual role they have in this scenario and whether they can actually be of value in the early identification of individuals at risk of developing CVD. Among these studies, is the one on uric acid (UA), which has behaved as a cardiovascular risk factor in several cross-sectional studies<sup>1-5</sup>. However, the presence of several confounding variables, such as obesity, alcohol consumption, age, diabetes and use of diuretics have made it difficult, to date, to indisputably establish the role of UA as an independent risk factor for cardiovascular events. </p>
      <p>The association between hyperuricemia and arterial hypertension has been under observation for more than a century<sup>1</sup>, but whether hyperuricemia has a causal role in arterial hypertension (AH) or if it is only a marker of the physiopathological process is yet to be elucidated. </p>
      <p>Recent experimental researches have established possible mechanisms through which hyperuricemia can cause hypertension. In animal models, UA caused a decrease in nitric oxide synthetase (NOS), afferent arteriole injury, increased renin production and renal tubule injury<sup>6,7</sup>. Moreover, a close association was demonstrated between hyperuricemia and metabolic syndrome in rats, due to a probable mechanism involving endothelial function inhibition<sup>8</sup>. It is known that insulin needs nitric oxide (NO) to stimulate glucose uptake and the NO availability is decreased when hyperuricemia occurs<sup>9</sup>. </p>
      <p>In this context, the inclusion of UA as variable for the stratification of cardiovascular risk seems interesting, as it is an easy-to-perform and low-cost test that can be useful in clinical practice, especially in individuals with metabolic syndrome and arterial hypertension. </p>
      <p>The present study aimed at evaluating the association between uric acid and cardiovascular risk factors in a non-hospitalized Brazilian population, covering a wide age range. </p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>The present was a cross-sectional study, of which sample was obtained from the database of a non-hospitalized population from the service of arterial hypertension of <italic>Hospital Universit&#225;rio Pedro Ernesto </italic>of <italic>Universidade do Estado do Rio de Janeiro </italic>(UERJ). The sample was obtained among patients submitted to preoperative admission assessment of non-cardiac surgeries and clinical evaluation for regular physical activity. Individuals of both sexes, aged 20 years or older, whose demographic data, clinical history, physical examination data and laboratory assessment including uric acid, glucose, serum lipids and creatinine levels were available, were considered eligible for study enrollment. </p>
      <p>The sample consisted of 756 individuals aged 20 years or older (mean of 50.3 years), of which 369 were males (48.8%). The patients were distributed by 20-year strata. </p>
      <p>All individuals had their demographic data collected followed by a clinical assessment to collect medical history data; additionally, a physical examination was carried out, which consisted of BP levels, weight and height measurement for BMI calculation and abdominal circumference measurement. A blood sample was collected after a 12-hour fast for the laboratory assessment, which included: glucose, insulin, HOMA-IR<sup>10</sup>, uric acid and creatinine levels. The glomerular filtration rate was also calculated through the Cockroft-Gault formula (140-age x weight/creatinine x 72 for men and for women, multiplied by the correction factor of 0.85), total cholesterol, HDL-c, triglycerides and LDL-c, through Friedewald's formula.</p>
      <p>The measurement of insulin and HOMA-IR calculation was carried out in 498 patients, in whom insulin was measured and HOMA-IR was calculated according to the formula: fasting insulin x plasma fasting glucose/405. The diagnosis of MS was considered according to the criteria of the I Guideline for Metabolic Syndrome<sup>11</sup>. The diagnosis of arterial hypertension was considered according to the V Brazilian Guideline for Arterial Hypertension<sup>12</sup>.</p>
      <p>The sample was stratified by quintiles of uric acid according to sex and 5 groups were constituted, G1 to G5, according to the crescent order of UA quintiles. For the male sex (M), the values corresponding to the quintiles of UA were <underline>&lt;</underline> 4.5, &gt; 4.5 and <underline>&lt;</underline> 5.2, &gt; 5.2 and <underline>&lt;</underline> 5. 9, &gt; 5.9 and <underline>&lt;</underline> 6.5, and &gt; 6.5 mg/dl. For the female sex (F), the values were <underline>&lt;</underline> 3.26, &gt; 3.26 and <underline>&lt;</underline> 3.9, &gt; 3.9 and <underline>&lt;</underline> 4.5 and &gt; 4.5 and <underline>&lt;</underline> 5.24 and &gt; 5.24 mg/dl, respectively for the first, second, third, fourth and fifth quintiles of uric acid. </p>
      <p>The data were analyzed using the statistical package "SPSS for Windows", release 8.0.0, Copyright SPSS Inc. 1989 - 1997.</p>
      <p>The following statistical methods were employed, with the level of rejection of the nullity hypothesis set at 0.05 or 5.0% (p = 0.05):</p>
      <disp-quote>
        <p>&#149; <italic>Analysis of variance (F) - </italic>used to compare the means of the variables that presented a normal distribution and homogeneity of variance at Bartley's test.</p>
        <p>&#149; <italic>Tukey's Test - </italic>used as complementary test for the analysis of variance, for comparison of means of the variables 2 x 2.</p>
        <p>&#149; <italic>Chi-square Test (</italic>c<italic><sup>2</sup>) - </italic>used to compare the frequency distribution of categorical variables of independent samples.</p>
        <p>&#149; <italic>Pearson's Correlation Test - </italic>used to analyze the correlation between continuous variables. </p>
      </disp-quote>
      <p>This study was approved by the Ethics Committee of <italic>Hospital Universit&#225;rio Pedro Ernesto</italic>, number 2322-CEP/HUPE, on December 10, 2008.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>The distribution of individuals was uniform by gender and age range analyzed (<xref ref-type="table" rid="en_aop00211tab01m-body2">Table 1</xref>). The means of systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol, triglycerides and creatinine significantly increased with the uric acid quintiles (<xref ref-type="table" rid="en_aop00211tab02m-body2">Table 2</xref>). For HDL-c and for the eGFR, the opposite occurred: the higher means of these variables were observed together with the lowest quintiles of UA (<xref ref-type="table" rid="en_aop00211tab02m-body2">Table 2</xref>). There was a prevalence of 48.3% of arterial hypertension, 33.6% of metabolic syndrome, 62.4% of overweight and obesity, 55.9% of hypercholesterolemia, 14.9% of altered fasting glycemia levels, 4.1% of diabetes, 24.9% of hypertriglyceridemia and 33.9% of low HDL levels in the total sample (<xref ref-type="table" rid="en_aop00211tab03m-body2">Table 3</xref>).</p>
      <p content-type="asset">
        <table-wrap id="en_aop00211tab01m-body2">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gt01-en.jpg"/></table-wrap>
      </p>
      <p content-type="asset">
        <table-wrap id="en_aop00211tab02m-body2">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gt02-en.jpg"/></table-wrap>
      </p>
      <p content-type="asset">
        <table-wrap id="en_aop00211tab03m-body2">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gt03-en.jpg"/></table-wrap>
      </p>
      <p>The prevalences of arterial hypertension, overweight/obesity (<xref ref-type="table" rid="en_aop00211tab03m-body2">Table 3</xref>) and metabolic syndrome (<xref ref-type="fig" rid="en_aop00211fig01m-body2">Figure 1</xref>) were significantly higher in the highest quintiles of uric acid (p &lt; 0.0001).</p>
      <p content-type="asset">
        <fig id="en_aop00211fig01m-body2">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gf01-en.jpg"/></fig>
      </p>
      <p>Regarding insulin and HOMA-IR, there was a higher predominance of the highest quintiles of insulin and HOMA-IR in the upper quintiles of uric acid with c<sup>2</sup> = 35.761 and p = 0.003 for HOMA-IR and c<sup>2</sup> = 31.393 and p = 0.012 for insulin (<xref ref-type="fig" rid="en_aop00211fig02m-body2">Figures 2</xref> and <xref ref-type="fig" rid="en_aop00211fig03m-body2">3</xref>). </p>
      <p content-type="asset">
        <fig id="en_aop00211fig02m-body2">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gf02-en.jpg"/></fig>
      </p>
      <p content-type="asset">
        <fig id="en_aop00211fig03m-body2">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gf03-en.jpg"/></fig>
      </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>This study brought contributions to the better understanding of the behavior of uric acid in relation to the clinical, metabolic and renal function variables associated with a higher cardiovascular risk, especially as it included a significant number of non-hospitalized individuals from the Brazilian population, whose data were scarcely available up to the present moment. Several studies have demonstrated that UA is an independent risk variable for cardiovascular risk factors<sup>2-5, 13-25</sup>.</p>
      <p>The population studied in the present study is a convenience sample, with no sample size calculation, and thus, cannot reflect the characteristics of the general population. On the other hand, the fact that it has a representative size and its non-hospital origin might have attenuated the possible selection bias. </p>
      <p>Regarding the mean age of the individuals in this series (50.3 years), there are no significant differences in relation to most studies on the subject<sup>3,18</sup>, except for the studies carried out in children and adolescents, such as the one by Bogalusa<sup>14</sup> or the trial carried out by Forman et al<sup>26</sup>, in which mean age was 61 years.</p>
      <p>Regarding the presence of risk factors, an increased prevalence of systemic arterial hypertension was observed in the present study (48.3%), in contrast with the expected rate of 31.0% for the Brazilian southeast region. A possible explanation for this fact might be the age range of these individuals, as elderly patients (&gt; 80 years) were included in the study, as well as the fact that 30.0% of the study population was older than 60 years, an age range at which the prevalence of arterial hypertension is known to be higher. </p>
      <p>MS was observed in 34.5% of these individuals, higher than the prevalences described in several studies<sup>24,27</sup>. It is noteworthy the fact that there are no national data on the subject for the purpose of comparison<sup>28</sup>. However, several studies have shown prevalences of MS that vary from 8.0% to 70.7%, depending on the age range. It is possible that the rates observed in the present study are due not only to the oldest age range to which these individuals belong, but also because this population presented more than 60.0% of obesity prevalence. </p>
      <p>Regarding diabetes, a similar prevalence was found to that observed in our country, which is 4.0%<sup>2</sup>, in large series, such as the Framingham study's<sup>2</sup>, which showed a prevalence of 2.7% of diabetes in the studied population.</p>
      <p>From the hemodynamic point of view, it can be observed that there were higher means of BP at the highest quintiles of UA, which corresponds to the results found by Conen et al<sup>29</sup>. </p>
      <p>As for the prevalence of arterial hypertension by quintiles of UA, it was clearly demonstrated that there was a significant association between these variables. This has been the result found in several publications, as it can be verified since 1994 with The Olivetti Heart Study<sup>23</sup>, where UA was associated with cardiovascular risk factors such as arterial hypertension or, in the study carried out by Perlstein et al<sup>4</sup> in 2,062 individuals, over a 21-year period, where arterial hypertension was also associated with higher quintiles of UA. Similarly the series by Mellen et al<sup>3</sup>, during a nine-year follow-up period, showed that arterial hypertension was more prevalent in patients with higher levels of UA, in a sample of 9,104 bi-ethnic individuals of both sexes.</p>
      <p>The biological explanation for this fact is supported by studies carried out with animal models with rats, which showed the development of arterial hypertension after the induction of hyperuricemia, caused by a probable decrease in nitric oxide in the renal macula densa and by direct stimulation of the renin-angiotensin system, with both mechanisms causing vasoconstriction and therefore, blood pressure increase<sup>6,7</sup>. </p>
      <p>However, on the other hand, there is the possibility that the increase in UA might be present in clinical conditions known to be pro-inflammatory, such as systemic arterial hypertension and MS, due to its antioxidant action, and therefore, represents only a biochemical defense mechanism<sup>30-32</sup> against atherosclerosis progression. Thus, it would not be an independent risk factor for these syndromes, but just part of the clinical picture. </p>
      <p>Regarding the metabolic variables, the prevalences of cholesterol, triglycerides and glucose intolerance were significantly higher in the higher quintiles of UA. The association with cholesterol and triglycerides was also found in the population studied by the Normative Aging Study. As for HDL-c, this study demonstrated an inverse association with the quintiles of UA and the same was verified in the 425 patients studied by Zocalli et al<sup>27</sup>.</p>
      <p>At the analysis of distribution of insulin and HOMA-IR quintiles, in relation to the quintiles of UA, the present study showed a significant association between higher quintiles of UA and higher quintiles of both insulin and HOMA-IR, a finding that is consistent with the ones observed by Formam et al<sup>26</sup>. Regarding HOMA-IR, Ishizaka et al<sup>24</sup> demonstrated higher prevalences of this variable by quintiles of UA. As for the presence of diabetes, the present study showed that the prevalence of this pathology was significantly higher in the groups with higher levels of UA, a result consistent with large longitudinal studies, such as the Framingham study<sup>2</sup> or the cohort of 9,104 individuals from the ARIC study<sup>3</sup>. These findings suggest that hyperuricemia is associated with insulin resistance, a condition underlying metabolic syndrome. </p>
      <p>Regarding the MS, there was also a higher prevalence in the groups presenting higher levels of UA, and similarly, the literature demonstrates such association, as it can be observed in the study by Kawada et al<sup>25</sup>, where 981 Japanese workers were assessed and which showed an association between MS and hyperuricemia. </p>
      <p>The Ishizaka<sup>24 </sup>also demonstrated a significant association between MS and UA levels, in a cross-sectional study of 8,144 individuals of both sexes, stratified by quartiles of UA. The highest prevalence of MS with increasing levels of UA was also demonstrated by a study carried out by Choi and Ford<sup>16, 17</sup> using data from NHANES. In some other studies, such as the one by Coutinho et al<sup>33</sup> and Desai et al<sup>15</sup>, it can be observed that US was associated with components that constitute MS, and the higher the number of components of the syndrome, the higher the association. </p>
      <p>Recently, in a study carried out in Brazil by Franco et al<sup>34</sup>, in hypertensive patients from Cuiaba, demonstrated a higher prevalence of MS in patients with hyperuricemia<sup>34</sup>.</p>
      <p>Among the limitations of the present study is the fact this is not a population-based sample. However, the number of individuals studied is quite significant and corresponds to a real scenario of assessment of cardiovascular risk factors in a non-hospital population. Data such as use of medications, alcohol consumption and presence of menopause were not available and are factors that can interfere, at least partially, with the observed results. Additionally, the present was a cross-sectional study, allowing only the analysis of the association of variables, without temporal inferences. </p>
      <p>
        <bold>Conclusions and perspectives</bold>
      </p>
      <p>The present study indicates the possibility that the uric acid is associated with cardiovascular risk variables and metabolic syndrome and that it can be useful in the individual cardiovascular risk assessment. </p>
      <p>The existence of a physiopathological rational basis to explain the association between the uric acid and cardiovascular risk factor, together with the fact that uric acid is easy to measure and the existence of the appropriate therapy to treat it, reinforce the need for new researches to better understand its participation in the cardiovascular disease scenario. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of master submitted by Monica Cristina Campos Barbosa, from <italic>Universidade do Estado do Rio de Janeiro</italic>.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Asociaci&#243;n entre &#225;cido &#250;rico y variables de riesgo cardiovascular en una poblaci&#243;n no hospitalaria</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La asociaci&#243;n entre &#225;cido &#250;rico (AU) y las variables de riesgo cardiovascular permanece controvertida en estudios epidemiol&#243;gicos. OBJETIVO: Evaluar la asociaci&#243;n entre el AU, presi&#243;n arterial (PA), &#237;ndices antropom&#233;tricos y variables metab&#243;licas en poblaci&#243;n no hospitalaria estratificada por quintiles de AU. M&#201;TODOS: En estudio observacional transversal, se evaluaron a 756 individuos (369 hombres), con promedio de edad de 50,3 &#177; 16,12 a&#241;os, divididos en quintiles de AU. Se obtuvieron PA, &#237;ndice de masa corporal (IMC), circunferencia abdominal (CA), dosis de AU, glucosa, insulina, HOMA-IR, colesterol (CT), LDL-c, HDL-c, triglic&#233;ridos (TG), creatinina (C). Se calcul&#243; la tasa de filtraci&#243;n glomerular estimada (TFGE) y considerada como hipertensi&#243;n arterial (HA) cuando la PA &gt; 140 x 90 mmHg, sobrepeso/obesidad (S/O) cuando IMC &gt; 25 kg/m&#178; y s&#237;ndrome metab&#243;lico (SM) de acuerdo con la I Directriz Brasile&#241;a de SM. RESULTADOS: 1) no hubo diferencia entre los grupos en la distribuci&#243;n por sexo y grupo de edad; 2) los mayores quintiles de AU presentaron mayores promedios de edad (p &lt; 0,01), IMC, CA (p &lt; 0,01), PAS, PAD (p &lt; 0,001), CT, LDL-c, TG (p &lt; 0,01), C y TFGE (p &lt; 0,001) y menor promedio de HDL-c (p &lt; 0,001); 3) el grupo con mayor quintil de AU revel&#243; mayores prevalencias de HA, S/O y SM (p &lt; 0,001); 4) mayores porcentuales de los menores quintiles de insulina (p &lt; 0,02) y de HOMA-IR (p &lt; 0,01) fueron encontrados en los menores quintiles de AU; 5) en an&#225;lisis de regresi&#243;n log&#237;stica, el AU y las variables que componen la SM se presentaron asociados a la ocurrencia de SM (p &lt; 0,01). CONCLUSI&#211;N: Mayores quintiles de &#225;cido &#250;rico se asociaron a un peor perfil de riesgo cardiovascular y a un peor perfil de funci&#243;n renal en la muestra poblacional no hospitalaria estudiada.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Enfermedades cardiovasculares</kwd>
        <kwd>&#225;cido &#250;rico</kwd>
        <kwd>hipertensi&#243;n</kwd>
        <kwd>factores de riesgo</kwd>
        <kwd>s&#237;ndrome metab&#243;lico</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="enda-body3">
          <label>
            <bold>Asociaci&#243;n entre &#225;cido &#250;rico y variables de riesgo cardiovascular en una poblaci&#243;n no hospitalaria</bold>
          </label>
          <p>
            <bold>Monica Cristina Campos Barbosa; Andr&#233;a Araujo Brand&#227;o; Roberto Pozzan; Maria Eliane Campos Magalh&#227;es; &#201;rika Maria Gon&#231;alves Campana; Flavia Lopes Fonseca; Oswaldo Luiz Pizzi; Elizabete Viana de Freitas; Ayrton Pires Brand&#227;o</bold>
          </p>
        </fn>
      </p>
      <p>Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La asociaci&#243;n entre &#225;cido &#250;rico (AU) y las variables de riesgo cardiovascular permanece controvertida en estudios epidemiol&#243;gicos. </p>
      <p><bold>OBJETIVO:</bold> Evaluar la asociaci&#243;n entre el AU, presi&#243;n arterial (PA), &#237;ndices antropom&#233;tricos y variables metab&#243;licas en poblaci&#243;n no hospitalaria estratificada por quintiles de AU. </p>
      <p><bold>M&#201;TODOS:</bold> En estudio observacional transversal, se evaluaron a 756 individuos (369 hombres), con promedio de edad de 50,3 &#177; 16,12 a&#241;os, divididos en quintiles de AU. Se obtuvieron PA, &#237;ndice de masa corporal (IMC), circunferencia abdominal (CA), dosis de AU, glucosa, insulina, HOMA-IR, colesterol (CT), LDL-c, HDL-c, triglic&#233;ridos (TG), creatinina (C). Se calcul&#243; la tasa de filtraci&#243;n glomerular estimada (TFGE) y considerada como hipertensi&#243;n arterial (HA) cuando la PA <underline>&gt;</underline> 140 x 90 mmHg, sobrepeso/obesidad (S/O) cuando IMC <underline>&gt;</underline> 25 kg/m<sup>2</sup> y s&#237;ndrome metab&#243;lico (SM) de acuerdo con la I Directriz Brasile&#241;a de SM. </p>
      <p><bold>RESULTADOS:</bold> 1) no hubo diferencia entre los grupos en la distribuci&#243;n por sexo y grupo de edad; 2) los mayores quintiles de AU presentaron mayores promedios de edad (p &lt; 0,01), IMC, CA (p &lt; 0,01), PAS, PAD (p &lt; 0,001), CT, LDL-c, TG (p &lt; 0,01), C y TFGE (p &lt; 0,001) y menor promedio de HDL-c (p &lt; 0,001); 3) el grupo con mayor quintil de AU revel&#243; mayores prevalencias de HA, S/O y SM (p &lt; 0,001); 4) mayores porcentuales de los menores quintiles de insulina (p &lt; 0,02) y de HOMA-IR (p &lt; 0,01) fueron encontrados en los menores quintiles de AU; 5) en an&#225;lisis de regresi&#243;n log&#237;stica, el AU y las variables que componen la SM se presentaron asociados a la ocurrencia de SM (p &lt; 0,01). </p>
      <p><bold>CONCLUSI&#211;N: </bold>Mayores quintiles de &#225;cido &#250;rico se asociaron a un peor perfil de riesgo cardiovascular y a un peor perfil de funci&#243;n renal en la muestra poblacional no hospitalaria estudiada.</p>
      <p><bold>Palabras clave:</bold> Enfermedades cardiovasculares/epidemiolog&#237;a, &#225;cido &#250;rico, hipertensi&#243;n, factores de riesgo, s&#237;ndrome metab&#243;lico. </p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Aunque los factores de riesgo cl&#225;sicos ya ten&#237;an su papel bien aclarado en el marco de las enfermedades cardiovasculares (ECV), diversas condiciones emergentes, denominadas marcadores de riesgo, no tienen todav&#237;a esta asociaci&#243;n definitivamente comprobada. Estudios se hacen necesarios para comprender el verdadero rol que juegan en esta escena y si de hecho podr&#225;n agregar valor en la identificaci&#243;n precoz de individuos bajo riesgo de desarrollar ECV. De entre estos estudios, se destaca aquello del &#225;cido &#250;rico, que viene comport&#225;ndose como un factor de riesgo cardiovascular en varios estudios longitudinales<sup>1-5</sup>. Sin embargo, la presencia de variables de confusi&#243;n, como obesidad, consumo de alcohol, edad, diabetes y utilizaci&#243;n de diur&#233;ticos, dificultaron, hasta el presente momento, establecer de forma inequ&#237;voca el papel del &#225;cido &#250;rico como un factor de riesgo independiente para eventos cardiovasculares. </p>
      <p>La asociaci&#243;n entre hiperuricemia e hipertensi&#243;n arterial viene siendo observada desde hace m&#225;s de un siglo<sup>1</sup>, sin embargo permanece obscuro si la hipeuricemia tiene un rol causal en la hipertensi&#243;n arterial o si es meramente un marcador del proceso fisiopatol&#243;gico. Recientes investigaciones en el campo experimental establecieron posibles mecanismos por los cuales la hiperuricemia podr&#237;a ocasionar hipertensi&#243;n. En modelos animales, el &#225;cido &#250;rico ocasion&#243; disminuci&#243;n del &#243;xido n&#237;trico sintetasa, injuria de la arteriola aferente, aumento en la producci&#243;n de renina y lesi&#243;n tubular renal<sup>6,7</sup>. Todav&#237;a m&#225;s, en ratones, se revel&#243; tambi&#233;n estrecha correlaci&#243;n entre hiperuricemia y s&#237;ndrome metab&#243;lico por probable mecanismo implicando la inhibici&#243;n de la funci&#243;n endotelial<sup>8</sup>. Se sabe que la insulina necesita de &#243;xido n&#237;trico para estimular la capacitaci&#243;n de la glucosa y la disponibilidad del &#243;xido n&#237;trico est&#225; disminuida cuando se produce hiperuricemia<sup>9</sup>. </p>
      <p>En este marco, la inserci&#243;n del AU como variable para la estratificaci&#243;n de riesgo cardiovascular puede ser interesante, por ser un examen de f&#225;cil realizaci&#243;n y de bajo costo, pudiendo ser &#250;til en la pr&#225;ctica cl&#237;nica, especialmente en portadores de s&#237;ndrome metab&#243;lico e hipertensi&#243;n arterial. </p>
      <p>El presente estudio tiene por objeto evaluar la asociaci&#243;n entre el &#225;cido &#250;rico y las variables de riesgo cardiovascular en una poblaci&#243;n no hospitalaria, brasile&#241;a, con amplia variaci&#243;n de edad. </p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Estudio transversal cuya muestra se obtuvo a partir de un banco de datos de una poblaci&#243;n no hospitalaria del sector de Hipertensi&#243;n Arterial del Hospital Universitario Pedro Ernesto de la Universidad del Estado de Rio de Janeiro (UERJ). La muestra se origin&#243; de pacientes sometidos a ex&#225;menes de admisi&#243;n, preoperatorios de cirug&#237;as no card&#237;acas y evaluaci&#243;n cl&#237;nica para la actividad f&#237;sica regular. Se consideraron como elegibles para inclusi&#243;n en este estudio, a los individuos de ambos sexos con m&#225;s de 20 a&#241;os, que tuvieran en sus registros datos demogr&#225;ficos, de historia cl&#237;nica y de examen f&#237;sico, adem&#225;s de evaluaci&#243;n laboratorial con dosificaci&#243;n de &#225;cido &#250;rico, glucemia, l&#237;pidos s&#233;ricos y creatinina. </p>
      <p>La muestra se constituy&#243; por 756 individuos con m&#225;s de 20 a&#241;os (promedio de 50,3 a&#241;os), siendo 369 del sexo masculino (48,8%). Los pacientes fueron distribuidos por estratos de 20 a&#241;os. </p>
      <p>En todos, se recolectaron datos demogr&#225;ficos y se llev&#243; a cabo una evaluaci&#243;n cl&#237;nica para la recolecci&#243;n de historia m&#233;dica y la realizaci&#243;n de examen f&#237;sico teniendo en cuenta la toma de la presi&#243;n arterial, el peso y la altura para el c&#225;lculo del IMC, la medici&#243;n de la circunferencia abdominal. Todav&#237;a se recolect&#243; la muestra sangu&#237;nea, en ayuno de 12 horas, para la determinaci&#243;n de los siguientes an&#225;lisis laboratoriales: glucosa, insulina, HOMA IR<sup>10</sup>, &#225;cido &#250;rico, creatinina. Tambi&#233;n se calcul&#243; la tasa de filtraci&#243;n glomerular, estimada por la f&#243;rmula de Cockroft-Gault (140-edad x peso/ creatinina x72 para los varones, y, para las mujeres, multiplicado por el factor de correcci&#243;n de 0,85), colesterol total, HDL-c, triglic&#233;ridos y el LDL-c, a trav&#233;s de la f&#243;rmula de Friedwald. </p>
      <p>La dosificaci&#243;n de insulina y el c&#225;lculo del HOMA-IR se llevaron a cabo en 498 pacientes, en los que la dosificaci&#243;n de insulina se realiz&#243; y el HOMA-IR se calcul&#243; de acuerdo con la f&#243;rmula: insulina de ayuno x glucosa plasm&#225;tica de ayuno/ 405. El diagn&#243;stico de s&#237;ndrome metab&#243;lico se consider&#243; seg&#250;n los criterios de la I Directriz de S&#237;ndrome Metab&#243;lico<sup>11</sup>. El diagn&#243;stico de Hipertensi&#243;n Arterial se consider&#243; conforme la V Directriz Brasile&#241;a de Hipertensi&#243;n Arterial<sup>12</sup>. </p>
      <p>La muestra se estratific&#243; por quintiles de &#225;cido &#250;rico seg&#250;n el sexo, y se conform&#243; 5 grupos de G1 a G5, en orden creciente de los quintiles de &#225;cido &#250;rico. Para el sexo masculino (M), los valores correspondientes a los quintiles de &#225;cido &#250;rico fueron <underline>&lt;</underline> 4, 5, &gt; 4,5 y <underline>&lt;</underline> 5, 2, &gt; 5,2 y <underline>&lt;</underline> 5, 9, &gt; 5,9 y <underline>&lt;</underline> 6, 5, y &gt; 6,5 mg/dl. Para el sexo femenino (F), los valores encontrados fueron <underline>&lt;</underline> 3, 26, &gt; 3,26 y <underline>&lt;</underline> 3, 9, &gt; 3,9 y <underline>&lt;</underline> 4,5 y &gt; 4,5 y <underline>&lt;</underline> 5,24 y &gt; 5,24mg/dl, respectivamente para el primer, segundo, tercero, cuarto y quinto quintiles de &#225;cido &#250;rico. </p>
      <p>Los datos se analizaron a trav&#233;s del programa estad&#237;stico "<italic>SPSS for Windows</italic>", versi&#243;n 8.0.0, <italic>Copyright SPSS Inc</italic>. 1989 - 1997. </p>
      <p>Se utilizaron los siguientes m&#233;todos estad&#237;sticos, tomando en consideraci&#243;n un 0,05% &#243; un 5% (p = 0,05) el nivel de rechazo de la hip&#243;tesis de nulidad: </p>
      <disp-quote>
        <p><italic>&#149; An&#225;lisis de varianza (F) -</italic>utilizada para la comparaci&#243;n de los promedios de las variables que presentan distribuci&#243;n normal y que tengan homogeneidad de varianzas por la prueba de Bartley. </p>
        <p><italic>&#149; Prueba de Tukey</italic>-usado como complementaci&#243;n del an&#225;lisis de Varianza, para la comparaci&#243;n de los promedios de las variables 2 a 2. </p>
        <p><italic>&#149; Prueba del chi-cuadrado</italic> (&#967;<sup>2</sup>) -utilizada para la comparaci&#243;n de las distribuciones de frecuencia de las variables categ&#243;ricas de muestras independientes. </p>
        <p><italic>&#149; Prueba de Correlaci&#243;n de Pearson - </italic>empleado para analizar la correlaci&#243;n entre variables continuas. </p>
      </disp-quote>
      <p>Este estudio fue aprobado por el Comit&#233; de &#201;tica del Hospital Universitario Pedro Ernesto, bajo n&#250;mero 2322-CEP/HUPE, en 10 de diciembre de 2008. </p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>La distribuci&#243;n de los individuos fue uniforme por g&#233;nero y por grupos de edad analizados (<xref ref-type="table" rid="es_a07tab01m-body3">Tabla 1</xref>). </p>
      <p content-type="asset">
        <table-wrap id="es_a07tab01m-body3">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gt01-es.jpg"/></table-wrap>
      </p>
      <p>Los promedios de PAS, PAD, colesterol total, triglic&#233;ridos y de creatinina aumentaron significativamente cuanto mayores fueron los quintiles de &#225;cido &#250;rico (<xref ref-type="table" rid="es_a07tab02m-body3">Tabla 2</xref>). Para el HDL-c y para la tasa de filtraci&#243;n glomerular estimada se produjo el contrario: los mayores promedios de estas variables estaban presentes en los menores quintiles de &#225;cido &#250;rico (<xref ref-type="table" rid="es_a07tab02m-body3">Tabla 2</xref>). </p>
      <p content-type="asset">
        <table-wrap id="es_a07tab02m-body3">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gt02-es.jpg"/></table-wrap>
      </p>
      <p>En la muestra total, se encontraron una prevalencia de 48,3% de hipertensi&#243;n arterial, 33,6% de s&#237;ndrome metab&#243;lico, 62,4% de sobrepeso y obesidad, el 55,9% de hipercolesterolemia, el 14,9% de glucemia de ayuno alterada, el 4,1% de diabetes, el 24,9% de hipertrigliceridemia y un 33,9% de HDL bajo (<xref ref-type="table" rid="es_a07tab03m-body3">Tabla 3</xref>). </p>
      <p content-type="asset">
        <table-wrap id="es_a07tab03m-body3">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gt03-es.jpg"/></table-wrap>
      </p>
      <p>Las prevalencias de hipertensi&#243;n arterial, sobrepeso/obesidad (<xref ref-type="table" rid="es_a07tab03m-body3">Tabla 3</xref>) y s&#237;ndrome metab&#243;lico (<xref ref-type="fig" rid="es_a07fig01m-body3">Figura 1</xref>) fueron significativamente mayores en los mayores quintiles de &#225;cido &#250;rico (p &lt; 0,0001). </p>
      <p content-type="asset">
        <fig id="es_a07fig01m-body3">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gf01-es.jpg"/></fig>
      </p>
      <p>Con relaci&#243;n a la insulina y al HOMA-IR, hubo mayor predominio de los mayores quintiles de insulina y HOMA-IR en los quintiles superiores de &#225;cido &#250;rico con &#967;<sup>2</sup> = 35,761 y p = 0,003 para HOMA-IR y &#967;<sup>2</sup> = 31,393 y p = 0,012 para insulina (<xref ref-type="fig" rid="es_a07fig02m-body3">Figuras 2</xref> y <xref ref-type="fig" rid="es_a07fig03m-body3">3</xref>). </p>
      <p content-type="asset">
        <fig id="es_a07fig02m-body3">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gf02-es.jpg"/></fig>
      </p>
      <p content-type="asset">
        <fig id="es_a07fig03m-body3">
          <graphic xlink:href="1678-4170-abc-96-03-0212-00011-gf03-es.jpg"/></fig>
      </p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Este estudio trajo contribuciones para el mejor entendimiento del comportamiento del &#225;cido &#250;rico en relaci&#243;n con las variables cl&#237;nicas, metab&#243;licas y de funci&#243;n renal asociadas a un mayor riesgo cardiovascular, sobre todo por tratarse de un trabajo con un n&#250;mero significativo de individuos de origen no hospitalaria, en una poblaci&#243;n brasile&#241;a, cuyos datos son poco disponibles hasta el presente momento. Varios estudios poblacionales demostraron ser el &#225;cido &#250;rico variable independiente de riesgo para factores de riesgo cardiovasculares<sup>2-5,13-25</sup>. </p>
      <p>La poblaci&#243;n estudiada en el presente estudio es una muestra de conveniencia, sin c&#225;lculo de tama&#241;o de la muestra, y, como tal, puede no reflejar las caracter&#237;sticas de la poblaci&#243;n en general. Por otro lado, el hecho de tener tama&#241;o representativo e ser de origen no hospitalaria puede haber atenuado el posible sesgo de selecci&#243;n. </p>
      <p>Con relaci&#243;n al promedio de edad de los individuos de esta serie (50,3 a&#241;os), no hay diferencias significativas con relaci&#243;n a la mayor parte de los estudios sobre el tema<sup>3,18</sup>, a excepci&#243;n de los trabajos realizados en ni&#241;os y adolescentes, como en el estudio de Bogalusa<sup>14</sup> o en el ensayo conducido por Forman et al<sup>26</sup>, cuya media de edad fue de 61 a&#241;os. </p>
      <p>Con relaci&#243;n a la presencia de factores de riesgo, se observ&#243; una prevalencia aumentada de HAS en el presente estudio (48,3%), en contraste con la tasa esperada de un 31,0% para la regi&#243;n sudeste brasile&#241;a. Una posible explicaci&#243;n para este hecho puede ser el grupo de edad de estos individuos, una vez que se incluyeron a pacientes adultos mayores (con edad superior a 80 a&#241;os) y aunque el 30% de la poblaci&#243;n del estudio ten&#237;an m&#225;s de 60 a&#241;os de edad, grupo de edad en la que la prevalencia de hipertensi&#243;n arterial es reconocidamente mayor. </p>
      <p>El SM se encontr&#243; en el 34,5% de estos individuos, ultrapasando las prevalencias descritas en diversas series<sup>24,27</sup>. Cabe recordar la ausencia de datos nacionales a dicho respeto para efecto de comparaci&#243;n<sup>28</sup>. Sin embargo, diversos estudios vienen se&#241;alando prevalencias de SM que variaron de un 8% a un 70,7%, dependiendo del grupo de edad. Es posible que las tasas observadas en el presente estudio son debidas no solamente al grupo de edad m&#225;s elevado de estos individuos, as&#237; como tambi&#233;n por ser esta una poblaci&#243;n con m&#225;s de 60% de prevalencia de obesidad. </p>
      <p>Para la diabetes, se encontr&#243; una prevalencia que se asemeja a aquella observada en nuestro pa&#237;s, que es del 4%<sup>2</sup> en grandes series, como el estudio de Framigham<sup>2</sup>, donde se constat&#243; un 2,7% de diabetes en la poblaci&#243;n estudiada. </p>
      <p>Desde el punto de vista hemodin&#225;mico, se nota que hubo mayores promedios de presi&#243;n arterial en los mayores quintiles de &#225;cido &#250;rico, correspondiendo a los resultados tambi&#233;n encontrados por Conen et al<sup>29</sup>. </p>
      <p>En cuanto a la prevalencia de hipertensi&#243;n arterial por los quintiles de &#225;cido &#250;rico, se demostr&#243; claramente haber una asociaci&#243;n significativa entre dichas variables. Este viene siendo el resultado encontrado en diversas publicaciones, conforme hemos podido verificar desde 1994 con el <italic>The Olivetti Heart Study<sup>23</sup>, </italic>donde el &#225;cido &#250;rico estuvo asociado a factores de riesgo cardiovasculares, como la hipertensi&#243;n arterial, o, como en el estudio conducido por Perlstein et al<sup>4</sup>, durante 21 a&#241;os, en 2.062 individuos, donde la hipertensi&#243;n arterial tambi&#233;n se asoci&#243; a mayores quintiles de &#225;cido &#250;rico. De forma similar, la serie de Mellen et al<sup>3</sup>, en seguimiento de 9 a&#241;os, con 9.104 individuos bi-&#233;tnicos y de ambos sexos, revel&#243; que la hipertensi&#243;n arterial fue m&#225;s prevalente en los pacientes con mayores niveles de &#225;cido &#250;rico. </p>
      <p>La explicaci&#243;n biol&#243;gica para tal hecho tiene como punto de apoyo las investigaciones realizadas en modelo animal con ratones, en las que, tras la inducci&#243;n de hiperuricemia, hubo desarrollo de hipertensi&#243;n arterial por probable reducci&#243;n del &#243;xido n&#237;trico en la m&#225;cula densa renal y por est&#237;mulo directo del sistema renina-angiotensina, siendo ambos mecanismos causadores de vasoconstricci&#243;n y, por tanto, de elevaci&#243;n de la presi&#243;n arterial<sup>6,7</sup>. </p>
      <p>No obstante, en la otra punta de esta argumentaci&#243;n, est&#225; la posibilidad de que el aumento del &#225;cido &#250;rico pueda estar presente en condiciones cl&#237;nicas sabidamente pro-inflamatorias, como la HAS y la SM, por su acci&#243;n antioxidante y, por tanto, representar solamente un mecanismo bioqu&#237;mico de defensa<sup>30-32</sup> contra la progresi&#243;n de la aterosclerosis. As&#237;, no ser&#237;a un factor independiente de riesgo para estos s&#237;ndromes, pero, antes, solamente parte del cortejo cl&#237;nico. </p>
      <p>Con relaci&#243;n a las variables metab&#243;licas, las prevalencias de colesterol, triglic&#233;ridos y de intolerancia a la glucosa fueron significativamente mayores en los mayores quintiles de AU. La asociaci&#243;n con colesterol y triglic&#233;ridos tambi&#233;n fue encontrada en la poblaci&#243;n estudiada en el <italic>Normative Aging Study. </italic> En cuanto al HDL-c, este estudio demostr&#243; asociaci&#243;n inversa con los quintiles de &#225;cido &#250;rico y el mismo se verific&#243; en los 425 pacientes estudiados por Zocalli et al<sup>27</sup>. </p>
      <p>En el an&#225;lisis de la distribuci&#243;n de los quintiles de insulina y HOMA-IR, con relaci&#243;n a los quintiles de &#225;cido &#250;rico, este trabajo revel&#243; de forma significativa una asociaci&#243;n entre mayores quintiles de &#225;cido &#250;rico y mayores quintiles tanto de insulina como de HOMA-IR, hallazgo consistente con la serie conducida por Forman et al<sup>26</sup>. Para el HOMA-IR, Ishizaka et al<sup>24</sup> demostraron mayores prevalencias de esta variable por quintiles de &#225;cido &#250;rico. En cuanto a la presencia de diabetes, el presente estudio evidenci&#243; que la prevalencia de esta patolog&#237;a fue significativamente mayor en los grupos con mayores niveles de &#225;cido &#250;rico, resultado consistente con grandes estudios longitudinales, como el estudio de Framingham<sup>2</sup> o la cohorte de 9.104 individuos del estudio ARIC<sup>3</sup>. Estos hallazgos sugieren que la hiperuricemia est&#233; asociada a la resistencia insul&#237;nica, condici&#243;n subyacente al s&#237;ndrome metab&#243;lico. </p>
      <p>Con relaci&#243;n al s&#237;ndrome metab&#243;lico, se encontr&#243;, tambi&#233;n, una mayor prevalencia en los grupos con mayores niveles de &#225;cido &#250;rico y, del mismo modo, la literatura se&#241;ala esta asociaci&#243;n, como podemos observar en el estudio conducido por Kawada et al<sup>25</sup>, donde 981 trabajadores japoneses fueron evaluados y se verific&#243; la asociaci&#243;n entre s&#237;ndrome metab&#243;lico e hiperuricemia. </p>
      <p>El Ishizaka<sup>24 </sup>tambi&#233;n demostr&#243; de manera significativa la asociaci&#243;n entre s&#237;ndrome metab&#243;lico y AU, al estudiar, de forma transversal, a 8.144 individuos de ambos sexos, estratificados por cuartiles de &#225;cido &#250;rico. La mayor prevalencia de s&#237;ndrome metab&#243;lico por niveles crecientes de &#225;cido &#250;rico tambi&#233;n se evidenci&#243; en el estudio llevado a cabo por Choi y Ford<sup>16,17</sup> utilizando datos del NHANES. En algunos otros trabajos, como el de Coutinho et al<sup>33</sup> y Desai et al<sup>15</sup>, se nota que el &#225;cido &#250;rico estuvo asociado a componentes que conforman el s&#237;ndrome metab&#243;lico, siendo esta asociaci&#243;n tanto mayor como mayor el n&#250;mero de componentes presentes de este s&#237;ndrome. </p>
      <p>Recientemente, en estudio llevado a cabo en el Brasil por Franco et al<sup>34</sup>, en pacientes hipertensos de Cuiab&#225;, se observ&#243; una mayor prevalencia de SM en pacientes portadores de hiperuricemia<sup>34</sup>. </p>
      <p>Como limitaci&#243;n del presente estudio, se destaca que esta no es una muestra de base poblacional. Sin embargo, el n&#250;mero de individuos estudiados es much&#237;simo expresivo y corresponde a una escena real de evaluaci&#243;n de factores de riesgo cardiovascular en una poblaci&#243;n no hospitalaria. Datos como la utilizaci&#243;n de medicamentos, etilismo y presencia de menopausa no estaban disponibles y son factores que pueden interferir, al menos parcialmente, en los resultados encontrados. Adem&#225;s de ello, se trata de estudio transversal, permitiendo tan solamente el an&#225;lisis de asociaci&#243;n de variables, sin inferencias temporales. </p>
      <p>
        <bold>Conclusiones y perspectivas</bold>
      </p>
      <p>El presente estudio indica la posibilidad de que el &#225;cido &#250;rico est&#233; asociado a las variables de riesgo cardiovascular y al s&#237;ndrome metab&#243;lico, pudiendo ser &#250;til en la evaluaci&#243;n del riesgo cardiovascular individual. </p>
      <p>La existencia de una base racional fisiopatol&#243;gica para explicar la relaci&#243;n del &#225;cido &#250;rico con los factores de riesgo cardiovascular, aliada a la facilidad de medici&#243;n del &#225;cido &#250;rico y de la existencia de terapia apropiada para tratarlo, refuerzan la necesidad de nuevas investigaciones para comprender mejor su participaci&#243;n en la escena de las enfermedades cardiovasculares. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes. </p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas. </p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de Disertaci&#243;n de Maestr&#237;a de Monica Cristina Campos Barbosa, por la Universidade do Estado do Rio de Janeiro. </p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
